Tag Archives: BIO Investor Forum

Cancer Stem Cell Therapy: Real Or Just Hype?

Stem Cell Therapy

Also known as tumor-initiating cells, cancer stem cells (CSC) have unique capability endemic to stem cells of self-renewal and differentiation, thereby causing tumor relapse and/or metastatis. While traditional cancer treatments focus on tumor shrinkage, it’s a distinct possibility that these agents do not effectively destroy all of the CSCs, causing the tumor to reappear. The CSC theory is relatively new, so the treatment pipeline is still in its early stages. Nathan Sadeghi-Nejad, a contributor to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIF2012 Company Snapshot: Chimerix

Chimerix

Our next Company Snapshot for next week’s BIO Investor Forum is Chimerix. They will be presenting on Tuesday, at 1:30pm, and will also be participating in a panel at the event, Choose Your Own Adventure — Late Stage Private Company Decisions on Wednesday. To learn more about the company before you get onsite, continue reading! Company Snapshot What is your company’s lead product or technology? Chimerix’s lead product is CMX001, a novel, broad-spectrum, oral antiviral that inhibits double-stranded Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,

#BIF2012 Company Snapshot: Profil Institute for Translational Medicine

profil_trans_med

For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room.   Company Snapshot What is your company’s lead product or technology? Based on collaborations with biopharma, Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

2012 BIO Investor Forum: Presenting Companies Making News

san-fran

Need a heart valve? Perhaps a bit more cartilage in your knees? Better yet, how about new blood vessels to bypass the old blocked ones? Amazingly, the days of relying upon animal or human cadavers’ tissue grafts to address these medical needs may possibly be drawing to a close. This is not Star Trek and this is not the Walt Disney’s optimistic science of Tomorrowland. As detailed in the Wall Street Journal last week, medical Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

A Start-Up Model Worthy of Consideration

attendessBusinessForum

Biotech LLCs are getting a lot of attention lately, and perhaps rightfully so. The Wall Street Journal’s Brian Gormley recently talked to Albert L. Sokol, a partner with Edwards Wildman Palmer, about the two venture-backed biotechs – Forma Therapeutics and Viamet Pharmaceuticals – that he helped convert to LLCs. In the WSJ article – Biotech Start-Ups See Benefits from Changing Structure, Lawyer Says – Sokol describes the benefits to start-ups and their venture investors, as Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,